Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 16/20 | 0.57 |
| ▸ | BCHE | P06276 | 10/20 | 0.53 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2458150 | 0.84 | ACHE (0.74) | ACHEBCHEPRMT6CYP2A6CYP2C19 | |
| SCHEMBL55096 | 0.84 | DAO (0.38) | ACHE | |
| SCHEMBL10738937 | 0.76 | PRMT6 (0.53) | ACHEBCHEPRMT6CYP2A6CYP2C19 | |
| SCHEMBL19049630 | 0.76 | ALOX5 (0.40) | — | |
| SCHEMBL12655116 | 0.76 | ACHE (0.63) | ACHEBCHEPRMT6CYP2A6CYP2C19 | |
| SCHEMBL27597427 | 0.75 | ACHE (0.52) | ACHEBCHEPRMT6CYP2A6CYP2C19 | |
| SCHEMBL8610492 | 0.74 | ACHE (0.61) | ACHEBCHEPRMT6CYP2A6CYP2C19 | |
| SCHEMBL8011063 | 0.74 | ACHE (0.61) | ACHEBCHEPRMT6CYP2A6CYP2C19 | |
| SCHEMBL687459 | 0.74 | ALDH1A1 (0.42) | CYP2A6CYP2C19 | |
| SCHEMBL9839086 | 0.74 | ACHE (0.61) | ACHEBCHEPRMT6CYP2A6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309563-B2 | Quinazoline derivatives useful as anti-tumor medicament | SHANGHAI ALLIST PHARMACEUTICALS, INC. (CN) | 2012-11-13 | — | — | US | disclosed |
| US-8044063-B2 | Quinazoline derivatives useful as anti-tumor medicament | SHANGHAI ALLIST PHARMACEUTICALS, INC. (CN) | 2011-10-25 | — | — | US | disclosed |
| US-20110245246-A1 | Quinazoline Derivatives Useful as Anti-Tumor Medicament | SHANGHAI ALLIST PHARMACEUTICALS, INC. (CN) | 2011-10-06 | — | — | US | disclosed |
| US-20080300248-A1 | Quinazoline Derivatives, Preparation Methods and Uses Thereof | SHANGHAI ALLIST PHARMACEUTICALS, INC. (CN) | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245246-A1 | Quinazoline Derivatives Useful as Anti-Tumor Medicament | TP53, NQO2, TOP1 | ACHE 1407/4885BCHE 2612/4885PRMT6 3434/4885 |
| US-20080300248-A1 | Quinazoline Derivatives, Preparation Methods and Uses Thereof | NQO2, AQP3, AQP1 | ACHE 947/4885BCHE 2186/4885PRMT6 3192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.